The effect of PN-1, a Traditional Chinese Prescription, on the Learning and Memory in a Transgenic Mouse Model of Alzheimer's Disease. by Yao, Zhi-Gang et al.
UC Irvine
UC Irvine Previously Published Works
Title
The effect of PN-1, a Traditional Chinese Prescription, on the Learning and Memory in a 
Transgenic Mouse Model of Alzheimer's Disease.
Permalink
https://escholarship.org/uc/item/0443q8dk
Authors
Yao, Zhi-Gang
Zhang, Ling
Liang, Liang
et al.
Publication Date
2013
DOI
10.1155/2013/518421
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 518421, 12 pages
http://dx.doi.org/10.1155/2013/518421
Research Article
The effect of PN-1, a Traditional Chinese Prescription, on
the Learning and Memory in a Transgenic Mouse Model of
Alzheimer’s Disease
Zhi-Gang Yao, Ling Zhang, Liang Liang, Yu Liu, Ya-Jun Yang, Lan Huang, Hua Zhu,
Chun-Mei Ma, and Chuan Qin
Comparative Medical Center, Institute of Laboratory Animal Science, Peking Union Medical College (PUMC),
Chinese Academy of Medical Science (CAMS), Beijing 100021, China
Correspondence should be addressed to Chuan Qin; qinchuan@pumc.edu.cn
Received 14 October 2012; Revised 13 January 2013; Accepted 15 January 2013
Academic Editor: Wei Jia
Copyright © 2013 Zhi-Gang Yao et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Traditional Chinese Medicine (TCM) is a complete medical system that has been practiced for more than 3000 years. Prescription
number 1 (PN-1) consists of several Chinese medicines and is designed according to TCM theories to treat patients with
neuropsychiatric disorders. The evidence of clinical practice suggests the benefit effects of PN-1 on cognitive deficits of dementia
patients. We try to prove and explain this by using contemporary methodology and transgenic animal models of Alzheimer’s
disease (AD).The behavioral studies were developed to evaluate thememory of transgenic animals after intragastric administration
of PN-1 for 3 months. Amyloid beta-protein (A𝛽) neuropathology was quantified using immunohistochemistry and ELISA. The
western blotting was used to detect the levels of plasticity associated proteins.The safety of PN-1 on mice was also assessed through
multiple parameters. Results showed that PN-1 could effectively relieve learning and memory impairment of transgenic animals.
Possible mechanisms showed that PN-1 could significantly reduce plaque burden and A𝛽 levels and boost synaptic plasticity. Our
observations showed that PN-1 could improve learning and memory ability through multiple mechanisms without detectable side
effects on mice. We propose that PN-1 is a promising alternative treatment for AD in the future.
1. Introduction
Cognitive impairment or dementia in the elderly is associated
with many disorders, such as Alzheimer’s disease (AD) and
vascular dementia (VaD) [1]. According to the traditional
Chinesemedicine (TCM), there is no distinction betweenAD
and VaD. The term “senile dementia” refers to a clinical syn-
drome characterized by the progressive decline of memory
and some related cognitive functions in the elderly [2]. In the
ancient Chinesemedicine literature, senile dementia falls into
the category of “dementia,” or “idiocysyndrome” resulting
from deficiency of kidney essence and marrow, obstruction
by phlegm and blood stasis, and so forth [3, 4]. According
to these traditional viewpoints, prescriptions composed of
a complex variety of many different herbs, minerals, or
animal parts are used to treat dementia clinically, such as Six
Flavors Rehmannia Pills (LiuWei Di HangWan), Nourish the
Heart Decoction (Yang Xin Tang) and Gastrodia and Uncaria
Drink (Tian Ma Gou Teng Yin) [5]. Prescription number 1
(PN-1) is a compound Chinese medicine designed entirely
based on TCM theories. From a western medical view, this
prescription has a wide range of pharmacological activities
in clinical application to treat cerebellar atrophy, dystaxia,
and cerebral palsy with minor side effects. In addition, the
clinical effectiveness on poor memory of the elderly suggests
a potential role of PN-1 in dementia therapeutics. Indeed,
the efficacy of PN-1 in senile dementia was demonstrated by
a nonblinded, open-label design performed by the Beijing
Xuanwu Hospital in China (unpublished data).
As the most common type of dementia in western medi-
cine, AD is a neurodegenerative disorder characterized clin-
ically by progressive memory loss and neuropathologically
by extracellular amyloid plaques [6]. The plaques are pri-
marily composed of aggregated 𝛽-amyloid (A𝛽) peptides
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derived from the 𝛽-amyloid precursor protein (APP) [7, 8].
Recent studies indicate that the increased A𝛽 production in
the hippocampus and cortex leads to synaptic impairment,
neuronal loss, and memory deficits [9–11]. Indeed, synaptic
dysfunction was found in the association cortices and hip-
pocampus of AD brain [12].These findings suggest the excess
production of A𝛽 peptides in the brain is a central event
in AD pathology [13, 14]. In addition, synapse is the basis
of learning and memory [15]. Hence, reactivating synaptic
function is the key to improve learning and memory. In this
study, we detected the effects of PN-1 on memory-associated
behavior tests in transgenic mouse models of AD. More-
over, A𝛽 burden and synaptic function were investigated to
understand the benefits of PN-1 to learning and memory
deficits.
2. Material and Methods
2.1. Transgenic Mice. The APPswe/PS1dE9 (APP/PS1) trans-
genic mouse model of AD overexpresses the Swedish
(K594M/N595L) mutation of APP together with presenilin
1 (PS1) deleted in exon 9 in a C57BL/6J genetic background.
Thesemice show learning andmemory deficits and increased
senile plaques in behavioral and neuropathological analyses
[16, 17]. The use of animals was in compliance with the
National Institutes of Health Guide for Care and Use of
Laboratory Animals.The study protocol was approved by the
Institutional Animal Care andUse Committee of the Institute
of Laboratory Animal Science (permit number: ILAS-PL-
2010-004). The study and all procedures were conducted
in accordance with institutional guidelines. All efforts were
made to minimize suffering.
2.2. Preparation for PN-1. PN-1 is composed of more than 20
kinds of Chinesemedicines, in which themain herbs used are
Radix Astragali, Radix Codonopsis, Rhizoma Atractylodis
Macrocephalae, and Cistanches Herba in a dry weight ratio
of 8 : 2 : 3 : 2. All components were authenticated macro-
scopically and microscopically according to pharmacopoeias
[18]. In details, macroscopic examinations includedmeasure-
ments of appearance, size, shape, color, texture, odor, taste,
fracture, and other characteristics of a herb. Microscopic
examinations determined characteristic elements of each
herb in both tissue and powder forms. In powder analysis,
each component was pulverized to 200mesh in size,mounted
on amicroscope slide, clearedwith chloral hydrate, lactochlo-
ral and/or sodium hypochlorite, and then examined for the
presence, size, shape, and numbers of characteristic elements
and inclusions such as vessels, calcium crystals, crystalline
fibers, stone cells, and starch grains. The examination proto-
cols followed theWorldHealthOrganization (WHO)Quality
Control Methods for Medicinal Plant Materials [19], the
Pharmacopoeia of the People’s Republic of China (CP) [18].
Amixture of powderedmaterials (500 g) were extracted three
times with total 20 L of distilled water in a hot-water bath for
3 h, and, after filtration, the filtrates were mixed together and
adjusted to a final concentration of 0.1mg/mL (equivalent to
dry weight of raw materials).
2.3. Experimental Procedures. ConcentratedPN-1 extractwas
dissolved or suspended in distilled water. Transgenic APP/
PS1mice at 5months of agewere randomized into the vehicle-
treated group (vehicle) and three experimental groups, inclu-
ding PN-1 0.6mg/kg (low dose), 1.2mg/kg (middle dose),
and 2.4mg/kg (high dose) once a day. Mice in the vehicle-
treated group were orally given distilled water. The doses
of the PN-1 used in this study were converted into raw
material weights and given orally to mice for 4 months. We
also introduced a positive control group, which was given
Aricept (generic name donepezil, 2mg/kg once a day) orally.
Aricept is approved by FDA for the clinical treatment of
AD and is usually used as a positive control in experiments
[20, 21]. In addition, the age-matched C57BL/6 wild-type
(WT) mice were required as control. Twenty animals (10
males and 10 females) were used for each group. Body weight,
food and water intakes were measured every two weeks
until behavior tests. At 8 months of age, the novel object
recognition (NOR) task was performed to detect recognition
memory of mice. One week after NOR task, spatial learning
and memory of animals were assessed by the Morris water
maze (MWM) test. Thereafter, all mice were sacrificed by
decapitation under intraperitoneal injection anesthesia using
sodium pentobarbital (45mg/kg).
2.4. Novel Object Recognition Task. The NOR task consisted
of a habituation phase, a training phase, and a testing phase.
During habituation, each mouse was habituated to the open-
field apparatus (30 cm wide, 45 cm long, and 20 cm high)
made of polyvinyl chloride plastic for 5min daily on 2
consecutive days in the absence of objects. No data were
collected during habituation. In the training trial, mice were
placed in the experimental apparatus and allowed to freely
explore the arena in the presence of two identical objects (blue
wooden cubes of side 3 cm) for 5min daily on 3 consecutive
days. The test phase was performed 24 h later. Each mouse
was placed in the arena with an object they explored during
the training phase (familiar object) and a new (novel) object
(a yellowwooden cylinder of diameter 3 cm and height 3 cm).
The open-field arena and the objects were cleaned thoroughly
between trials to ensure the absence of olfactory cues. A
mouse was scored as exploring an object when its head was
oriented toward the object within a distance of 1 cm or when
the nose was touching the object. Sitting on or going around
the objects was not considered exploratory behavior. The
exploration time for the familiar (𝑇
𝐹
) or the new object (𝑇
𝑁
)
during the test phase was videotaped and analyzed using
the Noldus Ethovision XT software (Noldus Information
Technology, Wageningen, The Netherlands). Memory was
defined by the discrimination index (DI) for the novel object
as the following formula: DI = (𝑇
𝑁
− 𝑇
𝐹
)/(𝑇
𝑁
+ 𝑇
𝐹
) × 100%
[22, 23].
2.5.MorrisWaterMazeTest. TheMorriswatermaze (MWM)
test was performed in a circular pool (100 cm in diameter)
filled with water at a temperature of 22 ± 1∘C. The water
was colored opaquewith powdered nonfatmilk. An overhead
video camera coupled to a computer and tracking soft-
ware (Ethovision system, Noldus Information Technology,
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Wageningen,TheNetherlands)was used to trackmovements.
The tank was placed in a dimly light, sound proof test
room with various visual cues. The pool was divided into
four quadrants of the equal area. A white platform (6 cm in
diameter and 29 cm high) was centered in one of the pool
quadrants. One day prior to hidden platform test, the mouse
was allowed to swim for 60 sec in the pool with the visible
platform projecting 1 cm above the water surface. The mouse
was then given two trial sessions each day for five consecutive
days, during which the platform was left in the same position
and submerged 0.5 cm below the water surface. The time
taken to reach the platform (escape latency) was measured,
and the average of two trials was determined. 24 h after the
last trial of the hidden platform test, the mouse was subjected
to a probe trial in which the platform was removed from the
pool, allowing the mouse to swim for 60 seconds in search of
it. The frequency of target platform crossings was recorded.
After the swim, the mouse was kept dry in a plastic holding
cage on an electric heater.
2.6. Assessment of Alzheimer Pathology. Brains were fixed
in formalin and embedded in paraffin. For each specimen,
30 serial sections of 5𝜇m thickness were coronally sliced
for two to three such series, spaced 50𝜇m apart. Sections
were deparaffinized in xylenes and rehydrated via an ethanol
gradient. Antigen retrieval was performed using 88% formic
acid treatment for 5min and incubated for 30min with
0.3% H
2
O
2
thereafter. Sections were blocked with 10% goat
serum and incubated with primary antibody overnight at
4∘C. The immunoreaction was visualized using horseradish
peroxidase (HRP) labeled IgG as secondary antibody incu-
bated at 37∘C for 30min and followed by diaminobenzidine
(ZSGB, Beijing, China) staining. For the quantification of
plaque levels, microscopic images of A𝛽 monoclonal anti-
body, 6E10 (1 : 1,000, Covance/Signet Laboratories, Dedham,
MA)-stained cortex, and hippocampus were captured. The
potential subregional variations of cortex and hippocampus
were systematically analyzed. For thioflavin-S staining, the
dewaxed sections were immersed in 1% thioflavin-S solution
for 5min and decolorized with 2 washes of 50% ethanol
followed by washing and dehydration in increasing ethanol
concentrations from 70% to 100%. The quantification of
plaque number and size after immunostaining were analyzed
using Aperio’s ImageScope Viewer software (Aperio. Tech-
nologies). Thioflavin-S stained sections were observed by an
OlympusBX40microscope (Olympus, Tokyo, Japan), and the
signal intensity was analyzed using ImageJ software (1.43u,
NIH, USA).
2.7. Quantitation of A𝛽 in Brain Extracts. The extraction of
soluble and insoluble A𝛽 species (including A𝛽40 and A𝛽42)
of the cortex and hippocampus homogenates was described
in previous studies [24–26]. Briefly, The frozen mouse cortex
and hippocampus were weighed and homogenized with ice-
cold Trisbuffered saline (TBS) consisting of 20mMTris-HCl,
150mM NaCl, and pH 7.4 to the frozen cortex at 4 : 1 (TBS
volume/brain wet weight). The homogenate was centrifuged
at 4∘C for 30min at 20,000 g.The supernatant containing sol-
uble A𝛽 peptide fraction (called TBS extract) was aliquoted
and then stored at −80∘C, and the pellet containing insoluble
A𝛽 was sonicated in an equal volume (v/v) of TBS plus 5M
guanidine HCl, pH 8.0, and incubated for 3-4 h at room
temperature. The homogenate were centrifuged at 4∘C for
30min at 20,000 g. The supernatant was collected (called
GuHCl extract) and regarded as the insoluble A𝛽 peptide
fraction. Protein concentrations were estimated in both frac-
tions using the NanoDrop 2000 spectrophotometer (Thermo
Scientific, Wilmington, DE, USA). A𝛽40 and A𝛽42 levels
were quantified by ELISA according to the manufacturer’s
recommendations (Invitrogen, CA, USA).
2.8. Western Blotting Analysis. Brains tissue samples were
homogenized using RIPA lysis buffer (50mM Tris-HCl pH
7.4, 150mMNaCl, 1% Triton X-100, 1% sodium deoxycholate,
and 0.1% SDS) containing 1mM PMSF. Total proteins from
brain samplesweremeasured using theNanoDrop 2000 spec-
trophotometer (Thermo Scientific, Wilmington, DE, USA).
Equal amounts of protein were loaded on a 10% SDS-PAGE
run at 90V for 1.5 h at room temperature and transferred
onto polyvinylidene fluoride (PVDF)membranes (Millipore,
Billerica, MA, USA) and then probed with the primary
antibodies overnight at 4∘C. The primary antibodies and
secondary antibodies were selected from the antibodies listed
in Supplemental Table S1, available online at http://dx.doi
.org/10.1155/2013/518421 including their dilution and com-
mercial supplier. Then, membranes were incubated with
peroxidase-labeled secondary antibody at room tempera-
ture for 1 h. Bands were visualized using enhanced chemi-
luminescent (ECL) substrate (Pierce, Rockford, IL USA)
and quantitated by densitometry using NIH ImageJ software
(1.43u, NIH, USA). Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) was used as a loading control. Specific bands
were quantified densitometrically, and the ratio between
intensity of phospho-CaMKII𝛼 and CaMKII𝛼, CREB and
phospho-CREB from the same homogenate were calculated.
2.9. Assessment of PN-1 Toxicity. Blood was collected after
sacrifice by cardiopuncture. Serum was collected by clotting
blood specimens for 10min at room temperature followed
by centrifugation at 2000 g for 10min at 4∘C. Serum was
immediately subjected to total bilirubin (TB), alanine amino-
transferase (ALT), aspartate aminotransferase (AST), crea-
tinine (Cr), and blood urea nitrogen (BUN) analysis using
commercial enzyme assays according to the manufacturer’s
instructions (Kang-Lan biotechnology Co. Ltd., Beijing).
Tissues of liver, kidney, brain, and so forth, were collected
after sacrifice. After fixation with 10% formaldehyde for
48 h, tissues were embedded in paraffin according to routine
procedures. Five 𝜇m thick sections were cut and stained with
hematoxylin-eosin (H&E) for histopathological evaluation.
Two expert pathologists at the Institute of Laboratory Ani-
mals blindly analyzed the tissue slices.
2.10. Statistical Analysis. All data were presented as means ±
SEM. The group differences of escape latencies in the MWM
test were analyzed using two-way ANOVA with repeated
measures. Treatments were compared using a one-way
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Figure 1: Effects of PN-1 treatment (mg/kg once a day) on the
performance of the novel object recognition (NOR) task. Data
represent means ± SEM (𝑛 = 17mice/group). ∗𝑃 < 0.05, ∗∗𝑃 < 0.01
versus the vehicle-treated group; #𝑃 < 0.05 versus the wild-type
group.
ANOVA followed by Dunnett’s multiple-comparison post
hoc test using the GraphPad Prism. Significant differences
were determined at 𝑃 < 0.05.
3. Results
3.1. PN-1 Treatment Improves Recognition Memory Deficits
in APP/PS1 Mice. As shown in Figure 1, the discrimination
index (DI) was significantly reduced by 87% for vehicle-
treated group compared to the wild-type (WT) group (𝑃 <
0.05).When comparedwith the vehicle-treated group,DIwas
significantly increased in Aricept- and PN-1-treated groups
by approximately 6–8 folds (𝑃 < 0.05 for the Aricept, low-
and middle-dose group; 𝑃 < 0.01 for the high-dose group).
3.2. PN-1 Treatment Improves Spatial Memory Deficits in
APP/PS1 Mice. In the hidden platform test (Figure 2(a)), the
vehicle-treated group showed significantly increased escape
latencies from day 2 compared to the wild-type group (𝑃 <
0.05 for day 2; 𝑃 < 0.01 for day 3–5). When compared with
the vehicle-treated group, escape latencies were significantly
decreased in PN-1-treated groups from day 4 (𝑃 < 0.05 for
day 4-5). At day 5, the Aricept-treated mice also showed sig-
nificantly decreased escape latency (𝑃 < 0.05). In the probe
trial (Figure 2(b)), vehicle-treated group showed significantly
decreased frequency of crossingwithin the platformquadrant
compared to wild-type group (𝑃 < 0.01). When compared
with the vehicle-treated group, the frequency was increased
in Aricept- and PN-1-treated groups (𝑃 < 0.05 for the Aricept
and low-dose group; 𝑃 < 0.01 for the middle- and high-dose
group). The typical behavioral traces from each group in the
probe trial appear in Figure 2(c).
3.3. PN-1 Treatment Reduces Plaque Burden in the Brains of
APP/PS1 Mice. Globally, results showed no A𝛽 deposition in
wild-type brains (figure not shown). As shown in Figure 3(a),
results showed significant reduction in the percentage of
cortical and hippocampal area occupied by amyloid plaques
in PN-1-treated groups compared to the vehicle-treated group
(𝑃 < 0.05 for all PN-1-treated groups). In the cortex, the area
of plaques was reduced by nearly 69% in PN-1-treated groups
(𝑃 < 0.01 for all PN-1-treated groups). In hippocampus, PN-
1 treatment also decreased the area of plaques by 57%–80%
in PN-1-treated groups (𝑃 < 0.05 for the low- and high-dose
group; 𝑃 < 0.01 for the middle-dose group). Moreover, the
staining distribution pattern of plaques was distinguishable
between groups (Figure 3(b)). PN-1 treatment showed sig-
nificant reduction of plaque number in the primary sensory
cortex (S1C, 𝑃 < 0.01 for the middle- and high-dose group)
and entorhinal cortex (EC, 𝑃 < 0.05 for the middle- and
high-dose group) by approximately 60%–70%, as compared
with the vehicle-treated group. In the hippocampus, the
plaque number in the stratum oriens (Or, 𝑃 < 0.01 for all
PN-1-treated groups), stratum radiatum (Ra, 𝑃 < 0.01 for
the high-dose group), and stratum lacunosum-moleculare
(LM, 𝑃 < 0.01 for all PN-1-treated groups) of CA1 area and
the molecular layer (Mo, 𝑃 < 0.01 for all PN-1-treated
groups) of dentate gyrus (DG) was also significantly decreas-
ed by nearly 70%, 70%, 60%, and 45%, respectively. However,
there is no significant difference in the number of plaques
in the motor cortex (MC) and hippocampal hilus (polymor-
phic layer of DG). In addition, PN-1 treatment showed the
significant effectiveness on plaque density decline (by nearly
80%) by assessing the signal intensity of thioflavin-S positive
plaques in the cortex (𝑃 < 0.01 for the middle- and high-
dose group) and hippocampus (𝑃 < 0.01 for all PN-1-treated
groups) as shown in Figure 3(c).
3.4. PN-1 Treatment Decreases A𝛽 Levels in the Brains of
APP/PS1Mice. To extract and characterize A𝛽1–40 andA𝛽1–
42 peptides present in mouse brains, we prepared soluble
A𝛽 peptide fraction (TBS extract) and insoluble A𝛽 peptide
fraction (GuHCl extract) by the sequential centrifugation
of cortical and hippocampal homogenates. In the wild-type
mouse brain, we detected much less soluble and insoluble
A𝛽 peptides (Figure 4). As shown in Figure 4(a), the results
showed the significant increase in soluble A𝛽1–40 level in
the low-dose group (𝑃 < 0.05) as well as the significant
decrease (by nearly 50%) in insoluble A𝛽1–40 level in the
middle- and high-dose group (𝑃 < 0.05), as compared
with the vehicle-treated group. For total cortical soluble and
insoluble A𝛽1–42 levels (Figure 4(b)), the results revealed
no significant PN-1 treatment effects (𝑃 > 0.05 for all
PN-1-treated groups). PN-1 treatment significantly lowered
hippocampal total soluble A𝛽1–40 (𝑃 < 0.05 for all PN-
1-treated groups, Figure 4(c)) and A𝛽1–42 (𝑃 < 0.01 for
all PN-1-treated groups, Figure 4(d)) levels by approximately
40% and 50%, respectively. However, there was no significant
effect of PN-1 on the levels of hippocampal insoluble A𝛽1–40
(𝑃 > 0.05 for all PN-1-treated groups, Figure 4(c)) and A𝛽1–
42 (𝑃 > 0.05 for all PN-1-treated groups, Figure 4(d)).
3.5. PN-1 Treatment Upregulates the Expressions of Plasticity-
Related Proteins. To further investigate the potential mecha-
nisms underlying the beneficial effects of PN-1 on memory
impairment of transgenic animals, presynaptic and postsy-
naptic proteins in the brain were analyzed using western
blotting. As compared with the wild-type group, the levels
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Figure 2: Effects of PN-1 treatment (mg/kg once a day) on the performance of the Morris water maze test. (a) The escape latency time in
5 days in the hidden platform test. Each point represents the mean latency of two trials per day for 5 consecutive days of testing. (b) The
frequency of crossing within the platform quadrant detected in the probe trial. (c) An illustration of typical behavioral traces in the probe
trial. Data represent means ± SEM (𝑛 = 17 mice/group). ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 versus the vehicle-treated group; ##𝑃 < 0.01 versus the
wild-type group.
of Syt 1, CaM, and BDNF expressions in the vehicle-treated
group were decreased by 0%, 45%, and 37%, respectively
(Figure 5(a), 𝑃 > 0.05 for Syt 1; 𝑃 < 0.05 for CaM and
BDNF). The levels of Syt 1 in the middle- and high-dose
of PN-1 treatment group were significantly upregulated by
approximately 1.5-fold, as compared with the vehicle-treated
group (𝑃 < 0.01). CaM levels were significantly increased by
78%, 159%, and 151% in the low-, middle-, and high-dose
of PN-1-treated groups, respectively (𝑃 < 0.05 for the low-
dose group, 𝑃 < 0.01 for the middle- and high-dose group).
Compared to the vehicle-treated mice, BDNF levels nearly
raised by 90% in all PN-1-treated groups (𝑃 < 0.05 for the
low- and high-dose group, 𝑃 < 0.01 for the middle-dose
group).
Considering the crucial role of phosphorylated proteins
in synaptic plasticity [27], we furtherly discussed the phos-
phorylation status of CaMKII𝛼 and CREB (Figure 5(b)). The
results showed no significant changes of CaMKII𝛼 andCREB
levels in each group after normalization using GAPDH (data
not shown). As compared with the wild-type group, the
ratios of p-CaMKII𝛼/CaMKII𝛼 and p-CREB/CREB in the
vehicle-treated group were significantly declined by 46% and
27%, respectively (𝑃 < 0.01 for p-CaMKII𝛼/CaMKII𝛼; 𝑃 <
0.05 for p-CREB/CREB). In all PN-1-treated groups, the
ratios of p-CaMKII𝛼/CaMKII𝛼 significantly raised by 79%,
91%, and 117%, respectively (𝑃 < 0.01 for all PN-1-treated
groups). In addition, the ratios of p-CREB/CREB in PN-1-
treated groups significantly raised by approximately 40% (𝑃 <
0.05 for all PN-1-treated groups).
3.6. PN-1 Treatment Shows No Detectable Side Effects on
Mice. During the long-term administration of PN-1, a bat-
tery of studies designed to detect possible side effects on
animals. However, there was no detectable difference in
body weight, food intake, or water intake between each
group over the 3-month treatment period (Supplementary
Figure S1). It suggested that PN-1 did not influence the
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Figure 3: Effects of PN-1 treatment (mg/kg once a day) on plaque pathology. (a) The percentage area occupied by plaques in the cortex and
hippocampus. (b)The average number of plaques per square millimeter in the cortical primary sensory cortex (S1C), entorhinal cortex (EC),
and motor cortex (MC) and hippocampal stratum oriens (Or), stratum radiatum (Ra), stratum lacunosum-moleculare (LM), molecular
layer (Mo), and dentate gyrus (DG) hilus. (c) The mean fluorescence intensity of thioflavin-S positive staining plaques in the cortex and
hippocampus (scale bar, 1 cm).Data representmeans± SEM (𝑛 = 6mice/group) from2 and 3 independent experiments. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01
versus the vehicle-treated group.
metabolic function of mice. Moreover, liver enzyme mea-
surements and kidney function tests were also performed
at the end of PN-1 administration. The results showed no
significant effect on the liver or kidney function, as reflected
by normal serum levels of total bilirubin (TB), alanine amino-
transferase (ALT), aspartate aminotransferase (AST), creati-
nine (Cr), and blood urea nitrogen (BUN) (Supplementary
Table 2). Microscopic examinations of the different tissues
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Figure 4: Effects of PN-1 treatment (mg/kg once a day) on A𝛽 levels. (a) The levels of cortical soluble and insoluble A𝛽1–40. (b) The levels
of cortical soluble and insoluble A𝛽1–42. (c) The levels of hippocampal soluble and insoluble A𝛽1–40. (d) The levels of hippocampal soluble
and insoluble A𝛽1–42. Data represent means ± SEM (𝑛 = 4 mice/group). ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, versus the vehicle-treated group; ##𝑃 <
0.01 versus the wild-type group.
(brain, liver, kidney, lung, heart, spleen, etc.) showed no
abnormal tissue architecture and cell morphology between
vehicle- and PN-1-treated animals (Supplementary Figure
S2).
4. Discussion
Although more than one hundred years had passed since AD
was first described by Alois Alzheimer in 1906, the treatment
is limited to the use of acetyl-cholinesterase inhibitors and
N-methylD-aspartic acid (NMDA) receptor antagonists [28].
In recent decades, many oriental medicine prescriptions have
documented the efficacy and effectiveness in AD therapeu-
tics, such as Yokukansan (Yi Gan San) [29–32] and Choto-
san (Gou Teng San) [33–35]. They all contain a large number
of components.These prescriptions exert potential benefits to
cognitive functions in clinical trials and animalmodel studies
and may unveil new strategy for dementia treatment as new
beneficial candidates to widen therapeutic options for AD.
In this study, we first assessed the effect of PN-1 on the
recognition memory for the NOR task, which is widely-
used to assess nonspatial working, declarative memory task
[36]. In our study, vehicle-treated mice could no longer dis-
criminate a novel from a familiar object. However, Aricept-
and PN-1-treated mice spent more time exploring novel
objects versus familiar ones. The findings may suggest that
PN-1 contributes to recognition memory consolidation. The
MWM test has been used to assess hippocampal-dependent
long-term spatial learning and memory [37, 38]. Vehicle-
treated mice exhibited significantly impaired spatial learning
and memory performance both in the hidden platform
test and probe trial. However, this impairment was ame-
liorated after PN-1 treatment, suggesting that PN-1 may
improve hippocampal-dependent long-term spatial learning
and memory. Besides, NOR and MWM data provide addi-
tional evidence that PN-1 may have clinical beneficial effects
on behavioral disturbances ofAlzheimer-type dementia, such
as getting lost behavior or misidentification [39, 40].
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Figure 5: Effects of PN-1 treatment (mg/kg once a day) on the expressions of plasticity-related proteins.The top panels show a representative
western blots, and the bottompanels show the quantitation of changes in protein levels by densitometry. (a)The levels of Syt 1, CaM, andBDNF
expressions. (b) The phosphorylation status of CaMKII𝛼 and CREB. Data represent means ± SEM (𝑛 = 6mice/group) from 3 independent
experiments. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 versus the vehicle-treated group. #𝑃 < 0.05, ##𝑃 < 0.01 versus the wild-type group.
Since the accumulation of A𝛽 peptides in the brain is
a central event of AD pathogenesis [13, 14] and strongly
associates with cognitive decline [41], we next analyzed neu-
ropathological changes after PN-1 treatment. The immuno-
histochemical results showed that PN-1 reduced plaque
number and plaque size most effectively in the cortex and
hippocampus of transgenic animals. Interestingly, the cur-
rent data also demonstrated that PN-1 could reduce plaque
number in subregions, such as cortical S1C and EC, hip-
pocampal CA1 area, and DG molecular layer. In addition,
we used thioflavin-S staining to detect dense-core plaques,
which have more fibrillar A𝛽42 with 𝛽 sheet secondary
structures associated with neuronal loss [42]. In our present
study, the intensity of thioflavin-S positive staining decreased
significantly following PN-1 treatment observed in the cortex
and hippocampus. Furthermore, accumulating evidence has
demonstrated that dense-core plaques associate with neuritic
and inflammatory pathology in AD patients as well as in
mouse models [43]. Therefore, our study also suggests the
potential effects of PN-1 on neuroinflammation. Overall,
neuropathological findings confirm that PN-1 can reduce
amyloid plaque burden located in the brain of the transgenic
mouse. We speculated that these changes are beneficial to
learning and memory.
The fact that PN-1 affects the plaque burden suggests that
it may influence A𝛽 metabolism in the brain. We observed
suppressed soluble A𝛽 (including A𝛽1–40 and A𝛽1–42) levels
in the hippocampus of PN-1-treated mouse. A recent study
has shown that soluble A𝛽 is associated with AD [44].
Especially, the relative levels of A𝛽42 are the key regulators
of A𝛽 aggregation into amyloid plaques. Thus, A𝛽42 has
been implicated as the initiatingmolecule in the pathogenesis
of AD [45, 46]. Additionally, A𝛽40 associates with amyloid
deposits in the cerebral vasculature (congophilic angiopathy,
CAA) [47] and also causes age-dependent learning defects
[48].Thedecreased solubleA𝛽 level after PN-1 treatmentmay
explain its ameliorating effects on hippocampus-dependent
tasks of learning and memory tested by NOR and MWM. In
contrast, neither hippocampal insoluble A𝛽1–40 and A𝛽1–42
levels nor cortical solubleA𝛽1–40 and insolubleA𝛽1–42 levels
were changed by PN-1 treatments. We speculate the effects
of PN-1 on A𝛽 levels are regional dependent, consistent with
the immunohistochemical results in our study. Indeed, the
inhomogeneous distribution of amyloid in the cerebral cortex
was demonstrated in AD patients and animal models [49,
50]. Further studies are needed to investigate the possible
mechanisms of PN-1 on A𝛽 metabolism, including A𝛽
production and clearance. In our study, endogenous A𝛽40
and A𝛽42 levels were also detected in the wild-type mouse
brain, which coincides with previous reports [51].
Considering the toxic effects of soluble A𝛽 on synaptic
functions [9–11], we next evaluated the actions of PN-1 on
presynaptic and postsynaptic proteins. We first assessed the
effect of PN-1 on CaMKII expression, which is a keymediator
in regulating synaptic plasticity and long-memory formation
[52]. The results showed there was no significant change
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in CaMKII𝛼 expression among wild-type, vehicle-, and PN-
1-treated mice. However, PN-1 treatment could strikingly
increase phosphorylated CaMKII𝛼 (Tyr286), which keeps
CaMKII at an active state [53]. Then, the raised CaM, which
is one of the upstreammolecules in the CaMKII pathway and
critical for CaMKII activation [54], was also detected in PN-
1-treated mice. Here, both findings suggest that PN-1 may
benefit the impaired long-term memory of transgenic mice
through ameliorated CaM/CaMKII/CREB signaling pathway
[55, 56]. This hypothesis was confirmed by the increased
phosphorylation ofCREB at Ser133, resulting in the activation
of gene transcription and long-term memory formation [57,
58]. Evidence suggests that phosphorylation of CREB at
Ser133 occurs in response to the BDNF expression [59]. The
raised BDNF following PN-1 administration in our study
suggests that BDNF is also involved in the effects of PN-1 on
the improvement of learning and memory deficits in trans-
genic mice by regulating CaMKII/CREB system [60]. Inter-
estingly, the raised synaptotagmin 1 (Syt 1) in PN-1-treated
groups implies that PN-1 also has the potential impact on
synaptic vesicles at presynaptic terminals, in which Syt 1 acts
as a synaptic vesicle-associated protein that triggers Ca2+-
sensitive, rapid neurotransmitter release [61, 62]. In this study,
we also detected the expressions of N-Methyl-D-aspartate
(NMDA) receptor 2B subunit (NR2B) and AMPA receptor
GluR1 subunit. However, there was no significant difference
of NR2B and GluR1 expressions among the six groups,
suggesting that PN-1 may act on NMDA receptor and AMPA
receptor through other mechanisms [63, 64]. Alternatively,
the recruitment of NMDA receptor and AMPA receptor to
postsynaptic membrane may also contribute to Ca2+ influx
and subsequent activation of CaMKII to trigger synaptic
plasticity observed in PN-1-treated mice abovementioned
[65, 66], whereas the total amounts of NMDA receptor and
AMPA receptor showed no significant change between each
group. These data provide us with other research interests in
the future.
We also examined the possible toxic side effects of PN-
1 on the animals. Results showed no significant side effect of
PN-1 on themetabolism, tissue structure, and function. In the
main compositions of PN-1, Radix Astragali, as a traditional
Chinese medicine, has been widely used for several thousand
years with a lowtoxicity [67, 68]. Both Radix Codonopsis
and Rhizoma Atractylodis Macrocephalae are usually used
to protect neurons in brain ischemia [69, 70] and improve
memory in dementia [71, 72] without significant side effect
[72, 73]. Cistanches Herba could promote neuronal growth
[74, 75] and enhance learning andmemory of themouse [74].
A new report, however, shows that Cistanches Herba induced
cytotoxicity in the male reproductive systems of mice [76]. In
our study, we found no evidence of toxicity to themale repro-
ductive systems. According to the TCM theories, Chinese
herbal prescriptions always contain numerous individual
herbs, which work synergistically together to magnify their
healing power and simultaneously counteract the potential
side effects of other herbs involved [5]. Anyways, further
studies are necessary to evaluate the long-term chronic
toxicity of PN-1 in the future.
5. Conclusions
In summary, although the detailed chemical components
and the exact targets of PN-1 are unknown now, the results
of this study demonstrate that chronic treatment with PN-
1 has a robust impact on memory deficits in transgenic
mouse models of AD without detectable side effects. The
potentialmechanisms involved in the PN-1 actions include (1)
reduction of amyloid burden in the cortex and hippocampus,
(2) inhibition of hippocampal A𝛽 levels, and (3) reactivation
of synaptic function-associated signal pathway. We think the
present study has given us more insight into the actions of
PN-1 in future research interests. Moreover, the development
of such multicomponent herbal medicines targeting multiple
sites could be useful for future drug discovery. Also, mech-
anism studies and identification of active compounds could
lead to new discoveries in biological and biomedical sciences.
These studies are underway.
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